Rubicon Research Ltd is an India-based pharmaceutical formulations company, which is focused on research and development, with a portfolio of specialty products and drug-device combination products targeting regulated markets, and particularly the United States. Its portfolio spans multiple dosage forms, including oral solids, oral liquids, nasal, and topical. Its technologies include RubiReten and RubiSRL. Its services include intellectual property evaluation and product design, formulation research development, analytical research development, technology transfer, dossier compilation and regulatory support, and clinical trials supplies. Its products are spread across many therapeutic areas, such as Analgesics/Pain Management, CVS, CNS, Hypokalemia, Skeletal Muscle Relaxants, NRT, Gastrointestinal, Metabolic, Immunosuppressant, and others. Others include Antipyretic, Hormonal Products, Diuretic, Antimuscarinics, Oral Rehydration Therapy, Over the Counter products, and Respiratory.As of 25 May 2026, RUBICON RESEARCH LIMITED share price is ₹944.15. The stock opened at ₹951.55, compared to its previous close of ₹951.20. During today's trading session, RUBICON RESEARCH LIMITED share price moved in the range of ₹940.40 to ₹963.95, with an average price of ₹952.17 for the day. Looking at its last 52-week, the stock has touched a low of ₹940.40 and a high of ₹963.95.
The market capitalization of RUBICON RESEARCH LIMITED is ₹15,671 Crs, with a P/E ratio of 76.0 and a dividend yield of 0.00%.